Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Theravance Biopharma (NASDAQ: TBPH) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 8, 2025, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.
Participants can join via telephone by dialing (800) 715-9871 from the US or (646) 307-1963 internationally, using Conference ID 3369474. The webcast will be accessible through the Investors section of Theravance Biopharma's website and will remain available for replay until June 7, 2025.
Theravance Biopharma (NASDAQ: TBPH) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e l'aggiornamento aziendale per giovedì 8 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call e una webcast simultanea alle 17:00 EDT (14:00 PDT/22:00 IST) dello stesso giorno.
I partecipanti potranno collegarsi telefonicamente componendo il numero (800) 715-9871 dagli Stati Uniti o il (646) 307-1963 dall'estero, utilizzando il codice conferenza 3369474. La webcast sarà disponibile nella sezione Investitori del sito web di Theravance Biopharma e resterà accessibile per la replica fino al 7 giugno 2025.
Theravance Biopharma (NASDAQ: TBPH) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización empresarial para el jueves 8 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia y una transmisión simultánea a las 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) ese mismo día.
Los participantes podrán unirse por teléfono marcando (800) 715-9871 desde EE. UU. o (646) 307-1963 internacionalmente, usando el ID de conferencia 3369474. La transmisión estará disponible en la sección de Inversores del sitio web de Theravance Biopharma y permanecerá accesible para reproducción hasta el 7 de junio de 2025.
Theravance Biopharma (NASDAQ: TBPH)는 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 8일 목요일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 5시 EDT(오후 2시 PDT/오후 10시 IST)에 컨퍼런스 콜과 동시 웹캐스트를 진행할 예정입니다.
참석자는 미국 내에서는 (800) 715-9871, 해외에서는 (646) 307-1963로 전화하여 회의 ID 3369474를 사용해 참여할 수 있습니다. 웹캐스트는 Theravance Biopharma 웹사이트 투자자 섹션에서 시청 가능하며 2025년 6월 7일까지 재생할 수 있습니다.
Theravance Biopharma (NASDAQ : TBPH) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 ainsi qu'une mise à jour commerciale pour le jeudi 8 mai 2025, après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion simultanée à 17h00 EDT (14h00 PDT/22h00 IST) ce même jour.
Les participants pourront se joindre par téléphone en composant le (800) 715-9871 depuis les États-Unis ou le (646) 307-1963 à l'international, en utilisant l'ID de conférence 3369474. La webdiffusion sera accessible via la section Investisseurs du site web de Theravance Biopharma et restera disponible en replay jusqu'au 7 juin 2025.
Theravance Biopharma (NASDAQ: TBPH) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate für Donnerstag, den 8. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr EDT (14:00 Uhr PDT/22:00 Uhr IST) eine Telefonkonferenz und eine gleichzeitige Webcast veranstalten.
Teilnehmer können sich telefonisch über die Nummer (800) 715-9871 aus den USA oder (646) 307-1963 international einwählen und die Konferenz-ID 3369474 verwenden. Der Webcast ist im Investor-Bereich der Theravance Biopharma-Website verfügbar und bleibt bis zum 7. Juni 2025 zum Nachsehen online.
- None.
- None.
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.
Conference Call Information
To participate in the live call by telephone, please dial (800) 715-9871 from the US or (646) 307-1963 for international callers, using the Conference ID 3369474. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 7, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2025-financial-results-on-may-8-2025-302436877.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) release Q1 2025 earnings?
How can investors join TBPH's Q1 2025 earnings call?
What time is Theravance Biopharma's Q1 2025 earnings call?
How long will TBPH's Q1 2025 earnings call replay be available?
